Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7

13 Oct 2020

Abstract excerpt

Chimeric antigen receptors (CARs) are fusion proteins that contain antigen-recognition domains and T cell signaling domains. Signaling lymphocytic-activation molecule F7 (SLAMF7) is a promising target for CAR T cell therapies of the plasma cell malignancy multiple myeloma (MM) because SLAMF7 is expressed by MM but not normal nonhematopoietic cells. We designed CARs targeting SLAMF7. We transduced human T cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33129371
DOI: 10.1016/j.ymthe.2020.10.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7PMID 33129371Read ↗

Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate efficacy and safety in preclinical models of Multiple MyelomaSemantic proximity Read ↗

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myelomaSemantic proximity Read ↗

Genetic engineering of cytolytic T lymphocytes for adoptive T‐cell therapy of neuroblastomaSemantic proximity Read ↗

Dual transgenesis of T cells with a CD44v6-specific chimeric antigen receptor and a suicide gene for the safe eradication of chemoresistant leukaemia and myelomaSemantic proximity Read ↗

Genomic Analyses of SLAMF7 CAR-T Cells Manufactured by <i>Sleeping Beauty</i> Transposon Gene Transfer for Immunotherapy of Multiple MyelomaSemantic proximity Read ↗

IL-7 receptor expression identifies suicide gene–modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectorsSemantic proximity Read ↗

Induction of leukemia-specific CD8+ cytotoxic T cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-alpha.Semantic proximity Read ↗

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.Semantic proximity Read ↗

Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.Semantic proximity Read ↗

Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.